153993-80-7

Basic information

• Product Name: Silane, [3-(4-bromophenyl)propoxy](1,1-dimethylethyl)dimethyl-
• CAS NO: 153993-80-7
• Molecular Formula: C15H25BrOSi
• Molecular Weight: 329.352
• Mol File: 153993-80-7.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Silane, [3-(4-bromophenyl)propoxy](1,1-dimethylethyl)dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Silane, [3-(4-bromophenyl)propoxy](1,1-dimethylethyl)dimethyl-(153993-80-7)
• EPA Substance Registry System: Silane, [3-(4-bromophenyl)propoxy](1,1-dimethylethyl)dimethyl-(153993-80-7)

Safety Data

• Hazardous Substances Data: 153993-80-7(Hazardous Substances Data)

Upstream product

• 288-32-4 1H-imidazole 
• 25574-11-2 3-(4-bromophenyl)propanol 
• 3650-78-0 methyl (E)-4-bromocinnamate 
• 1122-91-4 4-bromo-benzaldehyde 
• 75567-84-9 methyl 3-(4-bromopehynl)propanoate 
• 1643-30-7 3-(4-bromophenyl)propionic acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 642487-32-9 4-{4-[3-(tert-butyl-dimethyl-silanyloxy)-propyl]-phenyl}-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 
• 1056555-05-5 [4-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)phenyl]methanol 
• 1056555-08-8 tert-butyl{3-[4-(iodomethyl)phenyl]propoxy}dimethylsilane 
• 1056555-07-7 3-[4-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)phenyl]-2-cyano-N-cyclopropyl-N-(2,3-dichlorobenzyl)propanamide 

Relevant articles and documents

PYRAZINE DERIVATIVES

The invention concerns pyrazine derivatives of the Formula (I) or pharmaceutically-acceptable salts thereof; wherein each of n, m and R has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of bone-related disorders or conditions

Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors

Starting from known piperidine renin inhibitors, a new series of 3,9-diazabicyclo[3.3.1]nonene derivatives was rationally designed and prepared. Optimization of the positions 3, 6, and 7 of the diazabicyclonene template led to potent renin inhibitors. The substituents attached at the positions 6 and 7 were essential for the binding affinity of these compounds for renin. The introduction of a substituent attached at the position 3 did not modify the binding affinity but allowed the modulation of the ADME properties. Our efforts led to the discovery of compound (+)-26g that inhibits renin with an IC 50 of 0.20 nM in buffer and 19 nM in plasma. The pharmacokinetics properties of this and other similar compounds are discussed. Compound (+)-26g is well absorbed in rats and efficacious at 10 mg/kg in vivo.

RENIN INHIBITORS

The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds. These novel renin inhibitors are used in treating cardiovascular events and renal insufficiency.